secwatch.observer — SEC 8-K summary
======================================

Issuer:     Petros Pharmaceuticals, Inc. (PTPI)
CIK:        0001815903
Form:       8-K
Filed at:   2022-01-24T23:59:59+00:00
Accession:  0001104659-22-006678
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Petros Pharmaceuticals signs manufacturing agreement with Thermo Fisher's Patheon for Stendra
--------------------------------------------------------------------------------

- Metuchen (Petros subsidiary) and Patheon (Thermo Fisher) will collaborate on tech transfer and validation to manufacture Stendra at Patheon's Cincinnati facility.
- Agreement covers pharmaceutical development and technology transfer services to establish and validate Patheon's ability to supply Stendra.
- Commercial sale of product produced during the agreement requires a subsequent commercial manufacturing services agreement.
- After successful validation, parties will execute a commercial manufacturing agreement for release of commercially saleable products.
- Agreement effective until services completed; each party may terminate under customary conditions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815903/000110465922006678/0001104659-22-006678-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815903/000110465922006678/tm224219d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-006678

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer